OverviewSuggest Edit

Generation Bio is a genetic medicines company creating gene therapy utilizing its non-viral gene therapy platform. It combines three technologies: a cell-targeted lipid nanoparticle delivery system (ctLNP), a closed-ended DNA construct (ceDNA), and a high-capacity capsid-free biologics manufacturing process. In addition to its lead liver-targeted programs in hemophilia A and phenylketonuria (PKU), Generation Bio develops gene therapies for patients with diseases of skeletal muscle and the eye.

TypePublic
Founded2016
HQCambridge, MA, US
Websitegenerationbio.com

Latest Updates

Employees (est.) (Apr 2020)85
Job Openings33
Share Price (May 2021)$31.7(+3%)
Cybersecurity ratingAMore

Key People/Management at Generation Bio

Stephen Dipalma

Stephen Dipalma

Interim Chief Financial Officer
Doug Kerr

Doug Kerr

Chief Development Officer
Matthew Stanton

Matthew Stanton

Chief Scientific Officer
Jennifer Elliott

Jennifer Elliott

Chief Legal Officer
Geoff Mcdonough

Geoff Mcdonough

President & Chief Executive Officer
Mark Angelino

Mark Angelino

Founder & Chief Operating Officer
Show more

Generation Bio Office Locations

Generation Bio has an office in Cambridge
Cambridge, MA, US (HQ)
301 Binney St
Show all (1)

Generation Bio Financials and Metrics

Generation Bio Revenue

USD

Net income (FY, 2020)

(80.5m)

EBIT (FY, 2020)

(81.1m)

Market capitalization (14-May-2021)

1.8b

Closing stock price (14-May-2021)

31.7

Cash (31-Dec-2020)

62.9m
Generation Bio's current market capitalization is $1.8 b.
Annual
USDFY, 2020

General and administrative expense

22.6m

R&D expense

58.5m

Operating expense total

81.1m

EBIT

(81.1m)
Quarterly
USDQ2, 2020

General and administrative expense

4.3m

R&D expense

13.5m

Operating expense total

17.8m

EBIT

(17.8m)
Annual
USDFY, 2020

Cash

62.9m

Prepaid Expenses

5.4m

Current Assets

267.7m

PP&E

23.8m
Quarterly
USDQ2, 2020

Cash

171.7m

Prepaid Expenses

5.1m

Current Assets

306.2m

PP&E

22.8m
Annual
USDFY, 2020

Net Income

(80.5m)

Depreciation and Amortization

3.4m

Accounts Payable

(1.4m)

Cash From Operating Activities

(70.1m)
Quarterly
USDQ2, 2020

Net Income

(35.4m)

Depreciation and Amortization

1.5m

Accounts Payable

799.0k

Cash From Operating Activities

(33.3m)
USDQ2, 2020

Financial Leverage

1.1 x
Show all financial metrics

Generation Bio Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Generation Bio Online and Social Media Presence

Embed Graph

Generation Bio News and Updates

Generation Bio Presents Preclinical Data Demonstrating Broad Potential of Gene Therapy Platform at ASGCT and Reports First Quarter Financial Results

Durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model

Generation Bio to Present at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced three digital presentations at the American Society of Gene & Cell Therapy (ASGCT) 2021 Virtual Annual…

Generation Bio to Present at 20th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at …

Generation Bio Reports Fourth Quarter and Full Year 2020 Financial Results

$262.3 million cash balance at the end of 2020 bolstered by additional net proceeds of $211.3 million from follow-on offering, funding key milestones into 2024

Generation Bio Appoints Ron Cooper to Its Board of Directors

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, announced today that Ron Cooper has been appointed to its Board of Directors. The appointment is effective March 1, 2021.

Generation Bio Announces Pricing of Public Offering

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of a public offering of 8,000,000 shares of its common stock at a public offering price of $24.50 per sha…
Show more

Generation Bio Blogs

Toward a new paradigm in treatment for hemophilia A

A CONVERSATION WITH OUR CHIEF MEDICAL OFFICER DOUG KERR, MD, PHD, MBA In March we recognize Bleeding Disorders Awareness Month and the communities affected by these conditions, including hemophilia. As we continue to advance our efforts toward a durable, redosable gene therapy for hemophilia A, we r…

Connectivity

by THE GENERATION BIO TEAM What does connectivity mean to you? To us, it comes down to the ways in which we unite in our shared goals and vision of a better future. Connectivity is about building bridges between people, problem-solving together and all the pieces that make our day-to-day more enrich…

Generation Bio is 100 Strong

by THE GENERATION BIO TEAM Our team is what makes us who we are. And who we are is born from the constantly evolving nature of the team. We recently reached (and have now surpassed!) the 100-employee mark – a sign of both the success and the potential of Generation Bio. Together, we work toward our …

How well do your core values guide your organization? 2020 was the year we found out. (Part Two)

by THE GENERATION BIO TEAM This is our story, offered as a reflection from the hearts and minds of many across our organization. We are writing this post the same way we got through 2020. Together. An IPO during a pandemic is a mixture of planning and trust. One major objective of 2020 was to secure…

How well do your core values guide your organization? 2020 was the year we found out. (Part One)

by THE GENERATION BIO TEAM This year saw a lot. A worldwide pandemic. Civil unrest fueled by systemic racism. A global economy being challenged on many fronts. Throughout it all we asked ourselves, how does a company remain balanced in a world that is, right now, anything but? Is it possible to cont…

Our quality culture enables pioneering science

by SONIA RAZZETTI, PhD, VICE PRESIDENT OF QUALITY Quality is a mindset that enables our science at Generation Bio. It’s all about rigor. Responsibility. Integrity. And a commitment not just to do great work but to document that science so it can be understood, replicated, and built upon for years to…
Show more

Generation Bio Frequently Asked Questions

  • When was Generation Bio founded?

    Generation Bio was founded in 2016.

  • Who are Generation Bio key executives?

    Generation Bio's key executives are Stephen Dipalma, Doug Kerr and Matthew Stanton.

  • How many employees does Generation Bio have?

    Generation Bio has 85 employees.

  • Who are Generation Bio competitors?

    Competitors of Generation Bio include XBiotech, IntraBio and Marsala Biotech.

  • Where is Generation Bio headquarters?

    Generation Bio headquarters is located at 301 Binney St, Cambridge.

  • Where are Generation Bio offices?

    Generation Bio has an office in Cambridge.

  • How many offices does Generation Bio have?

    Generation Bio has 1 office.